Go,

Positions I held with publicly traded companies in my former life required me to become engaged in discussions with large investors (including hedge funds, mutual funds and pension funds) like those to which you refer; so I do not think I am naive regards Cardiogenics.

IMO Saunders and his hedge fund may be the only Institutional Investor in Cardiogenics. Given JAGH's share price prior to its dealings with Cardiogenics, I believe all institutional investors (if there ever were any) in JAGH were long gone prior to the Cardiogenics merger.

IMO Cardiogenics would be foolish to issue a PR regards a targeted start date for the Beta Site Study. IMO the next PR Cardiogenics issues regards the Beta Site Study should be the announcement that patients have been enrolled in the study. If Dr G wants to speculate on a date, he could speak to enrollment rates of patients which if maintained would place full enrollment of the study in some future month but I would encourage him not to make this speculation.

Ante